Overview

Active Pharmaceutical Ingredient Market Introduction:

Active Pharmaceutical Ingredient Market is estimated to value over USD 253 billion by 2027 end and register a CAGR of over 5.8% during the forecast period 2020 to 2027.

An abundance of capital is needed for the production of API, as the procedures require very systematic and precise protocols. As a result, there is no focus on physical manpower and setting up of costly manufacturing units. By adopting tactful and strategic outsourcing, the companies can emphasize more on their competencies, thereby, culminating in heightened productivity.

Active pharmaceutical ingredients (APIs) which have good quality, are crucial for the production of safe and effective medicines. However, it should be noted that not all pharmaceutical companies have adopted their own individual API manufacturing units. According to the market analysis, the rise of ailments such as cardiovascular and periodontal diseases, back pain, cancer and dental caries are factors which are expected to propel the active pharmaceutical ingredient market growth. The need for affordable medication and the rise in the volume of ANDA filings is projected to augment the market.

The acceptance of biologics and biosimilars and the rise in ailments such as cancer and chronic diseases, are factors which have been predicted to drive the market. However, aspects such as strict regulatory bodies and intense competition among other players, coupled with issues relating to price control regulations are all likely to pose potential threats to the market growth

Going by the product type, the market is divided into innovative and generic APIs. Innovative drugs segment is expected to rise owing to relaxed government rules and regulations. The segment for generic drugs is anticipated to grow in the future because of the affordability and patent expiry of branded drugs. This segment is predicted to expand in the developing nations owing to the untreated medical needs and rapid adoption of over-the-counter drugs.

With the type of manufacturer, the market is classified into merchant and captive APIs.

Captive API segment holds much strength in the market because of capitalist oriented focus with companies active in the production of availability of raw materials and top-of-the- line manufacturing facilities. With merchant API segment, it is forecasted to be a thriving segment precisely because of a growing need for biopharmaceuticals and exorbitant cost of in-house production of molecules. Moreover, because the captive production of APIs is costly, companies have begun to look to outsourcing to cut back on costs.

The biotech type is then categorized recombinant proteins, vaccines and antibodies. Synthetic segment has captured significant market share due to easy accessibility of raw materials, an abundance of revenue shares and relatively easy process of synthesis. Application-wise, the market is broken down into oncology, cardiology, endocrinology and neurology. The cardiology sub-segment has seen a spur in the market because of illnesses such as stroke and heart attack.

Some major global players in the APIs market include Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), AbbVie Inc. (US), Pfizer, Inc. (US), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), AstraZeneca plc (UK), Eli Lilly and Company (US).

Active Pharmaceutical Ingredient Market Segmentation:

By Type

Innovative Active Pharmaceutical Ingredients
Generic Active Pharmaceutical Ingredients

By Type of Manufacturer

Captive API Manufacturers
Merchant API Manufacturers
Merchant Innovative API Manufacturers
Merchant Generic API Manufacturers
Merchant Synthetic API Manufacturers
Merchant Biotech API Manufacturers

By Type of Synthesis

Synthetic Active Pharmaceutical Ingredients
Innovative Synthetic APIS
Generic Synthetic APIS
Biotech Active Pharmaceutical Ingredients
Innovative biotech APIs
Generic biotech APIs

By Product

Monoclonal Antibodies
Hormones & Growth Factors
Cytokines
Fusion Proteins
Recombinant Vaccines
Therapeutic Enzymes
Blood Factors

By Type of Drug

Prescription Drugs
Over-The-Counter Drugs

By Potency

Low-To-Moderate Potency Active Pharmaceutical Ingredients
Potent-To-Highly Potent Active Pharmaceutical Ingredients

By Therapeutic Application

Communicable Diseases
Oncology
Pain Management
Cardiovascular Diseases
Diabetes
Respiratory Diseases
Other Therapeutic Applications

By Region

North America
Europe
Asia- Pacific
Rest Of World

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the active pharmaceuticals market by type, by manufacturer, by type of synthesis, by product, by type of drug, by potency, by therapeutic application and by region
To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
To forecast and evaluate micro-markets and the overall market
To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and the rest of the world
To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com